{"id":1997,"date":"2024-08-27T13:08:55","date_gmt":"2024-08-27T13:08:55","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:08:55","modified_gmt":"2026-06-26T13:08:55","slug":"la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/","title":{"rendered":"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101"},"content":{"rendered":"\n<p><strong>MONTR\u00c8AL, 27 Ao\u00fbt, 2024 \u2013&nbsp;<\/strong>Find Th\u00e9rapeutiques Inc, une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies autoimmunes, a annonc\u00e9 aujourd&#8217;hui que la Food and Drug Administration (FDA) des \u00c9tatsUnis a approuv\u00e9 sa demande de nouveau m\u00e9dicament de recherche (IND) pour FTX101, ce qui permet \u00e0 la soci\u00e9t\u00e9 d&#8217;entamer l&#8217;\u00e9tude clinique de phase 1 pr\u00e9vue pour FTX101 chez des volontaires en bonne sant\u00e9. La soci\u00e9t\u00e9 pr\u00e9voit le d\u00e9but de l&#8217;\u00e9tude au cours du quatri\u00e8me trimestre 2024. &nbsp;<\/p>\n\n\n\n<p><em>\u00ab L&#8217;autorisation par la FDA de notre IND marque une \u00e9tape importante pour Find, nous permettant de proc\u00e9der \u00e0 l&#8217;\u00e9tude de phase 1 du FTX-101, une th\u00e9rapie de remy\u00e9linisation potentiellement innovante en cours de d\u00e9veloppement pour le traitement de la neuropathie optique chronique (NOC) \u00bb, a d\u00e9clar\u00e9 Philippe Douville, PDG de Find. \u00ab Nous sommes impatients d&#8217;\u00e9valuer le FTX-101 dans les \u00e9tudes cliniques de phase 1, ce qui nous rapprochera d&#8217;une solution pour les personnes souffrant de NOC pour lesquelles il n&#8217;existe actuellement aucune th\u00e9rapie approuv\u00e9e. \u00bb&nbsp;<\/em><\/p>\n\n\n\n<p>L&#8217;essai clinique de phase 1 devrait \u00eatre une \u00e9tude \u00e0 dose unique ascendante (SAD) et \u00e0 doses multiples ascendantes (MAD) afin d&#8217;\u00e9valuer la s\u00e9curit\u00e9, l\u2019innocuit\u00e9 et la pharmacocin\u00e9tique du FTX-101. &nbsp;Environs 80 patients seront recrut\u00e9s pour \u00e9valuer diff\u00e9rentes doses du compos\u00e9 FTX-101.<strong><\/strong><\/p>\n\n\n\n<p><strong>\u00c0 propos du FTX-101&nbsp;<\/strong><\/p>\n\n\n\n<p>Le compos\u00e9 principal de Find, FTX-101, est un agent remy\u00e9linisant de First-in-Class qui vise \u00e0 restaurer la vision des personnes souffrant de neuropathie optique chronique (NOC). FTX-101 est un peptide th\u00e9rapeutique rationnellement con\u00e7u qui cible la Plexine A1 et la Neuropiline 1, un complexe de r\u00e9cepteurs pr\u00e9sent dans le cerveau et dont l&#8217;implication dans la migration et la diff\u00e9renciation des cellules pr\u00e9curseurs d&#8217;oligodendrocytes en oligodendrocytes my\u00e9linisants a \u00e9t\u00e9 d\u00e9montr\u00e9e. Des donn\u00e9es pr\u00e9cliniques convaincantes sur le FTX-101 dans des mod\u00e8les de d\u00e9my\u00e9linisation montrent une forte activit\u00e9 de r\u00e9paration de la my\u00e9line.<\/p>\n\n\n\n<p><strong>\u00c0 propos de la neuropathie optique chronique&nbsp;<\/strong><\/p>\n\n\n\n<p>La neuropathie optique chronique est une maladie d\u00e9my\u00e9linisante grave et d\u00e9bilitante du nerf optique et des voies visuelles du cerveau. Malgr\u00e9 la disponibilit\u00e9 sur le march\u00e9 de m\u00e9dicaments immunomodulateurs qui contr\u00f4lent l&#8217;inflammation et les nouvelles pouss\u00e9es, il existe un besoin m\u00e9dical majeur non satisfait de trouver des traitements s\u00fbrs et efficaces capables de r\u00e9parer la my\u00e9line endommag\u00e9e dans le nerf optique et les voies visuelles du cerveau afin de pr\u00e9server la fonction axonale et de restaurer la vision dans le cas de la NOC. La NOC touche environ 90 000 patients aux \u00c9tats-Unis.<\/p>\n\n\n\n<p><strong>\u00c0 propos de Find&nbsp;<\/strong><\/p>\n\n\n\n<p>Find Therapeutics se consacre au d\u00e9veloppement de th\u00e9rapies de nouvelle g\u00e9n\u00e9ration pour traiter les maladies inflammatoires auto-immunes. La soci\u00e9t\u00e9 a \u00e9t\u00e9 lanc\u00e9e en 2020 avec des investissements de CTI Life Sciences, adMare BioInnovations et Domain Therapeutics et une licence exclusive de l&#8217;Universit\u00e9 de Strasbourg sur une technologie et un savoir-faire connexe initialement d\u00e9velopp\u00e9s par le Dr Dominique Bagnard. Visitez&nbsp;<a href=\"http:\/\/www.findtherapeutics.com\/\">www.findtherapeutics.com<\/a>&nbsp;pour plus de d\u00e9tails sur Find Therapeutics.<\/p>\n\n\n\n<p><strong>Contact pour les investisseurs :&nbsp;<\/strong><\/p>\n\n\n\n<p>Argot Partners<br>Sam Martin<br><a href=\"tel:646-233-4302\">646-233-4302<\/a><br><a href=\"mailto:Find@argotpartners.com%C2%A0\">Find@argotpartners.com&nbsp;<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>MONTR\u00c8AL, 27 Ao\u00fbt, 2024 \u2013&nbsp;Find Th\u00e9rapeutiques Inc, une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies autoimmunes, a annonc\u00e9 aujourd&#8217;hui que la Food and Drug Administration [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":1925,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[110],"class_list":["post-1997","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare\" \/>\n<meta property=\"og:description\" content=\"MONTR\u00c8AL, 27 Ao\u00fbt, 2024 \u2013&nbsp;Find Th\u00e9rapeutiques Inc, une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies autoimmunes, a annonc\u00e9 aujourd&#8217;hui que la Food and Drug Administration [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-27T13:08:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:08:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1199\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101\",\"datePublished\":\"2024-08-27T13:08:55+00:00\",\"dateModified\":\"2026-06-26T13:08:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/\"},\"wordCount\":567,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/\",\"name\":\"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"datePublished\":\"2024-08-27T13:08:55+00:00\",\"dateModified\":\"2026-06-26T13:08:55+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/find-therapeutics-fr-1744304415.png\",\"width\":1199,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News &#038; Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News &#038; Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare","og_description":"MONTR\u00c8AL, 27 Ao\u00fbt, 2024 \u2013&nbsp;Find Th\u00e9rapeutiques Inc, une soci\u00e9t\u00e9 biopharmaceutique sp\u00e9cialis\u00e9e dans le d\u00e9veloppement de th\u00e9rapies innovantes pour les maladies autoimmunes, a annonc\u00e9 aujourd&#8217;hui que la Food and Drug Administration [&hellip;]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/","og_site_name":"adMare","article_published_time":"2024-08-27T13:08:55+00:00","article_modified_time":"2026-06-26T13:08:55+00:00","og_image":[{"width":1199,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101","datePublished":"2024-08-27T13:08:55+00:00","dateModified":"2026-06-26T13:08:55+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/"},"wordCount":567,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/","name":"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101 | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","datePublished":"2024-08-27T13:08:55+00:00","dateModified":"2026-06-26T13:08:55+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/find-therapeutics-fr-1744304415.png","width":1199,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/la-fda-autorise-lind-pour-letude-clinique-de-phase-1-du-ftx-101\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News &#038; Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News &#038; Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"La FDA autorise l\u2019IND pour l\u2019\u00e9tude clinique de phase 1 du FTX-101"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1997","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1997"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1997\/revisions"}],"predecessor-version":[{"id":1998,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1997\/revisions\/1998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1925"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1997"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1997"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1997"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1997"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}